Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsed/refractory multiple myeloma

Trial Details

NCT ID
NCT06581640
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • CAR-T treatment
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

  • Age 18-80 years, no gender restrictions;
  • Diagnosed with refractory/relapsed multiple myeloma through physical examination, pathological examination, laboratory tests, and imaging studies;
  • Flow cytometry or histology confirms positive BCMA expression in myeloma cells;
  • As judged by the investigator, the expected survival time is \>3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →